Nycomed MRI liver imaging agent under review at FDA.
This article was originally published in The Gray Sheet
Executive Summary
NYCOMED S-095 MRI LIVER IMAGING AGENT PENDING AT FDA, Hafslund Nycomed Exec VP-R&D Trond Jacobsen said Nov. 8 at an Oppenheimer and Co. health care conference in New York City. A new drug application for the liver specific magnetic resonance imaging agent "was filed some weeks ago," Jacobsen reported. The agent allows study of "very small metastases or local lesion tumors in the liver."
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.